ilumetri
almirall s.a - tildrakizumab - psoriasis - immunosuppressantit, interleukiinin estäjät, - ilumetri on tarkoitettu hoitoon aikuisilla, joilla on kohtalainen tai vaikea läiskäpsoriaasi, jotka ovat ehdokkaita systeeminen hoito.
rizmoic
shionogi b.v. - naldemedine tosilate - ummetus - lääkkeet ummetus, perifeerinen opioidi-reseptorin antagonistit - rizmoic on tarkoitettu hoitoon opioidien aiheuttama ummetus (oic) aikuisilla potilailla, joille on aiemmin hoidettu laksatiivinen.
poteligeo
kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastiset aineet - poteligeo on tarkoitettu aikuisille potilaille, joilla on t-solulymfooman (mf) tai sézary oireyhtymä (ss), jotka ovat saaneet vähintään yksi aikaisempi systeeminen hoito.
lixim 70 mg lääkelaastari
drossapharm arzneimittel handelsgesellschaft gmbh - etofenamate - lääkelaastari - 70 mg - etofenamaatti
bylvay
albireo - odevixibat - cholestasis, intrahepatic - bile- ja maksanhoito - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 ja 5.
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immunoseerumit ja immunoglobuliinit, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulantit, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.
plerixafor seacross 20 mg/ml injektioneste, liuos
seacross pharma (europe) limited - plerixafor - injektioneste, liuos - 20 mg/ml - pleriksafori
tetralysal 150 mg kapseli, kova
galderma nordic ab - lymecycline - kapseli, kova - 150 mg - lymesykliini
tetralysal 300 mg kapseli, kova
galderma nordic ab - lymecycline - kapseli, kova - 300 mg - lymesykliini